Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg, Kurt A. Schalper, Scott Gettinger, Amit Mahajan, Roy S. Herbst, Anne C. Chiang, Rogério Lilenbaum, Frederick H. Wilson, Sacit Bulent Omay, James B. Yu, Lucia B. Jilaveanu, Thuy Tran, Kira F. Pavlik, Elin Rowen, Heather Gerrish, Annette Komlo, Richa Gupta, Hailey Wyatt, Matthew Ribeiro, Yuval Kluger, Geyu Zhou, Wei Wei, Veronica Chiang, Harriet M. Kluger
Topics & Concepts
MedicinePembrolizumabResponse Evaluation Criteria in Solid TumorsInternal medicineCohortInterim analysisClinical endpointBrain metastasisOncologyLung cancerCancerPhases of clinical researchMetastasisRandomized controlled trialClinical trialImmunotherapyBrain Metastases and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment